Knight Therapeutics (OTCMKTS:KHTRF – Get Free Report) is projected to post its results before the market opens on Thursday, November 5th. Analysts expect the company to announce earnings of $0.0098 per share and revenue of $90.74 million for the quarter.
Knight Therapeutics Stock Performance
Knight Therapeutics stock opened at $8.24 on Thursday. Knight Therapeutics has a twelve month low of $4.11 and a twelve month high of $8.31. The firm’s 50 day moving average price is $7.37 and its two-hundred day moving average price is $6.08.
Wall Street Analyst Weigh In
Separately, Royal Bank Of Canada reaffirmed an “outperform” rating on shares of Knight Therapeutics in a research note on Friday, August 7th. One investment analyst has rated the stock with a Buy rating. Based on data from MarketBeat.com, the company has a consensus rating of “Buy”.
View Our Latest Research Report on KHTRF
About Knight Therapeutics
Knight Therapeutics Inc is a Canadian specialty pharmaceutical company focused on acquiring, licensing, commercializing and, in some cases, developing innovative prescription medicines. The company targets areas of significant unmet medical need, including oncology, rare diseases, neurology, infectious diseases and other specialty-care markets.
Knight works with pharmaceutical and biotechnology partners to bring approved or late-stage therapies to patients. Its activities generally include regulatory support, market access, commercialization and distribution rather than large-scale discovery research.
See Also
- Five stocks we like better than Knight Therapeutics
- Why Rising Rates Could Break the Bull Market Before AI Spending Can Save It
- Boeing Got Its MAX 10 Approval, But Q3 Delivered a Reality Check
- The Invisible AI Backbone: Corning’s AI Fiber Play
- Heavy Metal: Why Nucor Could Be an Overlooked AI Infrastructure Winner
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
